formulate

(redirected from formulating)
Also found in: Dictionary, Thesaurus, Legal.

formulate

/for·mu·late/ (for´mu-lāt)
1. to state in the form of a formula.
2. to prepare in accordance with a prescribed or specified method.

formulate

(fôr′myə-lāt′)
tr.v. formu·lated, formu·lating, formu·lates
To prepare according to a specified formula.

for′mu·la′tion n.
for′mu·la′tor n.

formulate

(for′myŭ-lāt″)
1. To construct or prepare a recipe or formula.
2. In pharmacology, to make a medication according to a recipe or formula.
formulation (for″myŭ-lā′shŏn)
References in periodicals archive ?
Kits are available of innovative skin care product prototypes exhibiting the SensiMap Formulating Concept.
Enough relates to seeking meaning in a quantity of information by formulating a perspective on which to build and determining what one needs to know.
Formulating is done with aliphatic amine, anhydride, polyamide, Lewis-acid, and cycloaliphatic chemistries.
New reclaiming processes offer the promise of providing an economical product for formulating with scrap rubber in value added products, such as adhesives and sealants.
Choices available within hardeners allow formulating with a complete range of handling characteristics and final cured properties.
Americhem also anticipates formulating a liquid concentrate that would be diluted to formulate ESD coatings applied by conventional roll or dip coating methods or perhaps rotogravure printing.
The concept of Total Cost of Partnering is introduced and used as a decision support tool in formulating and managing a channel strategy.
Company specializes in custom formulating multifunctional concentrates to meet specific design requirements.
These trends require an in-depth review of the backroom operations of composite decking production - both formulating and processing advances taking place around the world.
Choices available within hardener categories allow formulating with a complete range of handling characteristics and final cured properties.
This report provides end users with a guide for strengths and weaknesses of specific vendor solutions as well as a broad understanding of the outlying costs and considerations, which are critical to formulating a successful project strategy.
OTCBB:ENVC) - a biotechnology company with two potential $1 billion dollar blockbuster cardiovascular drugs approved for final FDA Phase III human trials - announced today that Cardinal Health (NYSE:CAH) is one month ahead of the original schedule in its process of formulating the ANGIOGENIX(TM) drug according to cGMP FDA standards.